|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome显示文摘AIM: To determine whether Lactobacillus casei strain Shirota (Yakult ) can alter small intestinal bacterial overgrowth (SIBO), as tested by the lactulose breath test, and whether this is associated with changes in symptoms in irritable bowel syndrome (IBS). METHODS: 18 patients with IBS (Rome Ⅱ criteria), who showed an early rise in breath hydrogen with lactulose (ERBHAL), consumed 65 mL of Yakult daily for 6 wk. Lactulose breath test was repeated at the end of the treatment period. Symptoms were recorded daily using a 10 cm visual analogue scale. RESULTS: 14 patients completed the study, 9 (64%) had reversal of ERBHAL, with the median time of f irst rise in breath hydrogen increasing from 45 to 75 min (P = 0.03). There was no signifi cant improvement in the symptom score with probiotic therapy, except for wind (P=0.04). Patients commencing with at least moderate symptoms and who no longer had ERBHAL at the end of treatment, showed improvement in the overall symptoms scores [median fi nal score 5.3 (IQR3.9-5.9), 55% reduction; n=6] to a greater extent than those who had had persisting ERBHAL [final score 6.9 (5.0-7.0), 12% reduction; n = 5; P = 0.18]. CONCLUSION: Yakult is effective in altering fermentation patterns in the small bowel, consistent with reducing SIBO. The loss of ERBHAL was associated with reduced symptoms. The true interpretation of these fi ndings awaits a randomised, controlled trial. | Jacqueline S Barrett Kim EK Canale Richard B Gearry Peter M Irving Peter R Gibson | 2008 | World Journal of Gastroenterology2008，14，32： | 16 |
| 2 | Time to clinical response and remission for therapeutics in inflammatory bowel diseases: what should the clinician expect, what should patients be told?显示文摘An awareness of the expected time for therapies to induce symptomatic improvement and remission is necessary for determining the timing of follow-up, disease(re)assessment, and the duration to persist with therapies, yet this is seldom reported as an outcome in clinical trials. In this review, we explore the time to clinical response and remission of current therapies for inflammatory bowel disease(IBD) as well as medication, patient and disease related factors that may influence the time to clinical response. It appears that the time to therapeutic response varies depending on the indication for therapy(Crohn's disease or ulcerative colitis). Agents with the most rapid time to clinical response included corticosteroids, calcineurin inhibitors, exclusive enteral nutrition, aminosalicylates and anti-tumor necrosis factor therapy which will work in most patients within the first 2 mo. Vedolizumab,methotrexate and thiopurines had a longer time to clinical response and can take several months to achieve maximal efficacy. Factors affecting the time to clinical response of therapies included use of concomitant therapy, disease duration, smoking status, disease phenotype and advanced age. There appears to be marked variation in time to clinical response for therapies used in IBD which is further influenced by disease and patient related factors. Understanding the expected time to therapeutic response is integral to inform further decision making, maintain a patientcentered approach and ensure treatment is given an appropriate timeframe to achieve maximal benefit prior to cessation. | Abhinav Vasudevan Peter R Gibson Daniel R van Langenberg | 2017 | World Journal of Gastroenterology2017，23，35： | 4 |
| 3 | Venous and arterial disease in inflammatory bowel disease显示文摘 | Victoria P Tan Alvin Chung Bryan P Yan Peter R Gibson | 2013 | J Gastroenterol Hepatol2013，，7： | 3 |
| 4 | Fault-zone seals in siliciclastic strata of the Columbus Basin,offshore Trinidad显示文摘 | Gibson R G | 1994 | AAPG1994，78，9： | 2 |
| 5 | Simulation modeling:some programing required显示文摘 | Gibson R | 1997 | IIE Solutions1997，，2： | 1 |
| 6 | A new and highly efficient grubbs initiator for ring-opening metathesis polymerization显示文摘 | Robson D A Gibson V C Davies R G | 1999 | Macromolecules1999，32，19： | 1 |
| 7 | Stochastic Convenience Yield and the Pricing of Oil Contingent Claims 显示文摘 | Gibson R Schwartz E S | 1990 | The Journal of Finance1990，65，3： | 1 |
| 8 | Carbohydrate Preferences of Bifidobacterium Species Isolated from the Human Gut显示文摘 | Palframan R J Gibson G R Rastall R A | 2003 | Curt Issues Intest Microbiol2003，，4： | 1 |
| 9 | Yeast re- sponses to stresses associated with industrial brewery han- dling 显示文摘 | Gibson B R Lawrence S J Leclaire J P R | 2007 | FEMS Microbiology Reviews2007，31，5： | 1 |
| 10 | A Two-Stage Continuous Culture System to Study lle Effect of Supplemental Alpha-laatalbumin and Glycomacropetide on Mixed Cultures of Human Cut Bacte- ria Challenged with Enteropathogenic Escherichia Coil and Salmonella Serotype Typhimurium显示文摘 | BRUCK W M GRAVERHOLT G GIBSON R | 2003 | J Appl Mi erobiol2003，95，： | 1 |
| 11 | The effectiveness of repair strategies used by people with heating losses and their conversational partners 显示文摘 | Caissie R Gibson C | 1997 | The Volta Review1997，99，： | 1 |
| 12 | 显示文摘 | GIBSON R SMITH M D SPARY C J | 2005 | Environ Sci Technol2005，39，： | 1 |
| 13 | 显示文摘 | Gibson I R Best S M Bonfield W | 1999 | Biomed Mater Res1999，44，： | 1 |
| 14 | Nucleotide sequence, transcriptional analysis,and expression of genes encoded within the form I CO2 fixation operon of Rhodobacter sphaeroides显示文摘 | Gibson J L Falcone D L Tabita F R | 1991 | J Biol Chem1991，266，14： | 1 |
| 15 | Network Attached Storage Architec- ture显示文摘 | Gibson G A van Meter R | 2000 | Communications of ACM2000，43，119： | 1 |
| 16 | Dietary modulation of the human colonicmicrobe: introducing the concept of Prebiotics显示文摘 | Gibson G R | 1995 | J Nutr1995，125，： | 1 |
| 17 | Plan strain and axially symmetric consolidation of a clay layer on a smooth impervious base显示文摘 | GIBSON R E SCHIFFMAN R L PUS L | | 0，，4： | 1 |
| 18 | Symptoms, aetiology and serological analysis of sweet potato virus disease in Uganda 显示文摘 | Gibson R W Mpembe I Alicai T | 1998 | Plant Pathology1998，47，1： | 1 |
| 19 | Prebiotics,probiotics and human gutmicrobilogy显示文摘 | Fooks LJ Fuller R Gibson GR | 1999 | Int Dairy J1999，9，1： | 1 |
| 20 | in vitro fermentability of dextran,oligodextran and maltodextrin by human gut bacteria显示文摘 | OLANO M E MOUNTZOURIS K C GIBSON G R | 2000 | British Journal of Nutrition2000，83，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员